Pharmaceuticals News
Subscribe to pharmaceutical news about research, development, manufacturing and marketing of prescription and over the counter drugs. Find the latest on FDA approvals, compliance, competition, management and distribution of pharmaceutical products as well as pharmaceutical business intelligence.
Microvascular Therapeutics to Present New Clinical and Preclinical Data on CardiSon™ and Solv™ at the 2026 Contrast Media Research Symposium
Presentations highlight superior echocardiographic performance of CardiSon and 70% reduction in myocardial infarct size with ultrasound-activated Solv in a preclinical model. - October 30, 2026 - Microvascular Therapeutics, Inc.
V1 Health Expands Its Science-Led Educational Resources on Daily Supplements and Healthy Aging
V1 Health, a Romanian wellness and dietary supplement brand, is expanding its online educational resources focused on evidence-informed nutrition, ingredient transparency, and healthy aging. The initiative reflects a growing need for accessible information that helps consumers distinguish... - October 29, 2026 - V1 Health S.R.L
Emerge Weight Loss Extends Compassionate GLP-1 Care to Adults Living with Obstructive Sleep Apnea
As landmark research shows tirzepatide can cut sleep apnea severity by roughly half, Emerge brings medically supervised, whole-person telehealth care to the millions of adults who wake up every morning still exhausted. - October 27, 2026 - Emerge Weight Loss, LLC
BIX 2026 Counts Down to Opening with Post-GLP-1 Session on the Next Obesity Treatment Market
BIX 2026 Highlights Post-GLP-1 Obesity Market - October 23, 2026 - RX
At USEReady’s Dallas Breakfast with Agents Session, Executives Say AI Success Starts with Strategy, Not Software
Leaders from USEReady, HF Sinclair, US LBM, Columbia University and Sigma Computing made the case that quick wins and a unified data foundation have to be built together. - October 20, 2026 - USEReady
Advantage Healthcare Services Launches ACE, a Provider Education Initiative to Close Gaps in Behavioral Health Treatment Adherence
Advantage Healthcare Services announced the launch of ACE (Advantage Clinical Education™), a provider education initiative designed to help behavioral health care teams address treatment adherence challenges. The inaugural program explores strategies to reduce relapse risk, improve continuity of care, and support better outcomes for individuals living with bipolar disorder and schizophrenia through practical education and companion resources. - October 13, 2026 - Advantage Healthcare Services
USEReady Announces Migrate2Quick to Accelerate Legacy BI Migration to Amazon Quick
Expanded approach combines AWS Transform and USEReady’s MigratorIQ agentic platform to help enterprises bring legacy BI, business logic, and governed metrics into an AI-powered decision environment. - October 08, 2026 - USEReady
Lizzie McDermid Honored as a Woman of the Month for September 2026 by P.O.W.E.R. (Professional Organization of Women of Excellence Recognized)
Lizzie McDermid of Aurora, Colorado has been recognized as a Woman of the Month for September 2026 by P.O.W.E.R. (Professional Organization of Women of Excellence Recognized). This prestigious distinction acknowledges her contributions and achievements in pediatric pharmacy operations, leadership,... - October 02, 2026 - P.O.W.E.R. Professional Organization of Women of Excellence Recognized
Microvascular Therapeutics to Present Phase II CardiSon™ Data at 40th International Bubble Conference in Chicago
Next-generation ultrasound enhancing agent demonstrated improved left ventricular opacification and significantly reduced acoustic shadowing - October 02, 2026 - Microvascular Therapeutics, Inc.
RxProtect and HealthBook+ Partner to Deliver Medication Savings and Personalized Care
Collaboration combines RxProtect's nurse-driven member support with HealthBook+'s clinician-led AI platform to better advocate for members taking high-cost medications. - September 30, 2026 - HealthBook+
ALS TDI to Convene ALS Research, Industry, and Community Leaders at 2026 Summit and White Coat Affair Gala
This October, two Boston events will bring people together to share research updates, build connections, and accelerate progress for people with ALS. - September 23, 2026 - ALS Therapy Development Institute
USEReady Joins OpenAI Partner Network to Accelerate Enterprise AI Adoption
Combining production-grade GenAI and Agentic AI expertise with OpenAI technology to help enterprises move from AI experimentation to measurable business impact. - September 23, 2026 - USEReady
SignaBlok Awarded NIH NIDDK Grant to Develop Novel TREM-1 Antagonist Drug for Inflammatory Bowel Disease
SignaBlok, Inc. has been awarded a Phase I SBIR grant from the NIH NIDDK to advance the development of a novel mechanism-based therapy for inflammatory bowel disease (IBD). The award supports SignaBlok's differentiated approach to targeting TREM-1 in IBD. - September 18, 2026 - SignaBlok, Inc.
Rob Merrill Named CEO of TFives, Life Sciences AI Compliance
TFives appoints 25-year healthcare regulatory veteran as CEO to lead enterprise adoption of compliance-ready AI governance for the Life Sciences industry. - September 17, 2026 - TFives
Microvascular Therapeutics Appoints George Kokke to Board of Directors
Veteran family office executive and healthcare investor brings more than 30 years of investment, finance, and board experience. - September 17, 2026 - Microvascular Therapeutics, Inc.
Beyond the Scale: Emerge Weight Loss Expands GLP-1 Telehealth Care to Support Women Living With PCOS and Endometriosis
As emerging research illuminates tirzepatide's metabolic and anti-inflammatory effects, Emerge extends compassionate, medically supervised weight loss care from board-certified providers to women whose health needs reach far beyond a number on the scale. - September 02, 2026 - Emerge Weight Loss, LLC
Helix BioMedix Completes $2 Million Private Placement to Advance Xeroderma Pigmentosum Development Program
Financing strengthens balance sheet and accelerates advancement of proprietary DNA repair technology targeting UV-induced DNA damage. - August 29, 2026 - Helix BioMedix, Inc
BIX 2026 to Spotlight the Future of Stem Cell and Global Biopharma M&A
BIX 2026 unveils keynotes on stem cell advances for nervous system diseases and global biopharma M&A trends, bringing together biotech leaders, investors, and researchers to drive collaboration and innovation. - August 21, 2026 - RX
New 2026 Report Reveals an AI/LLM Gap Between Biopharma Sponsors and Their CROs/Vendors
Life Science Strategy Group looks beyond frontier-AI hype to show how biopharma teams use AI and LLMs in daily work, and where their CRO and vendor partners are falling short. 71% of sponsors rate their own AI/LLM output highly. Only 27% say the same of their CROs and vendors. - August 12, 2026 - Life Science Strategy Group, LLC
Lobbie Continues Building the Modern Clinic Platform with Enhanced Patient Billing
Today’s clinics can strengthen cash flow and streamline operations building more sustainable businesses by unifying patient acquisition, intake, clinical workflows, billing, memberships, and payments in one integrated platform. - August 06, 2026 - Lobbie
Microvascular Therapeutics Highlights the Future of Ultrasound Theranostics in Comprehensive Wiley Review
Microvascular Therapeutics, Inc. (MVT) today announced publication of a comprehensive review in Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology (WIREs Nanomedicine and Nanobiotechnology), a leading peer-reviewed journal with a 2025 Journal Impact Factor of 8.6, entitled,... - July 28, 2026 - Microvascular Therapeutics, Inc.
Pacto Medical Wins Red Dot Design Concept Award 2026 for Slimshot® Compact Prefilled Syringe
Slimshot® recognized in Medical Devices & Technology Concept category; product selected for display at Red Dot Design Museum in Singapore. - July 14, 2026 - Pacto Medical
Validation Management Solutions Expands Leadership Team with the Appointment of Remoun Amin as Partner
Validation Management Solutions (VMS) has appointed Remoun Amin as Partner, marking an important milestone in the company's growth. With more than two decades of life sciences experience, Amin strengthens VMS's ability to deliver expert CQV, calibration, and temperature mapping services while advancing its vision to help clients build assurance that scales with them. - July 09, 2026 - Validation Managment Solutions
GW Health Announces Strategic AI Partnership to Expand Communications Capabilities
Announced at the Cannes Lions Festival, the collaboration pairs senior communications expertise with innovative scientific storytelling. - June 22, 2026 - GW Health Agency
DSV Launches Direct Luxembourg–indianapolis Pharma Air Route to Improve Temperature-Controlled Deliveries
DSV launches the latest expansion of its Air ThermoDirect solution through Indianapolis International Airport, strategically strengthening pharmaceutical supply chains with enhanced cold-chain connectivity from one of the United States’ fastest-growing life sciences and healthcare logistics... - June 09, 2026 - DSV
Alera Bio Appoints David McCullough as Chief Executive Officer
Alera Bio announced the appointment of David McCullough as Chief Executive Officer. An experienced biotechnology executive, McCullough will lead corporate strategy, financing, organizational development, and execution of the company’s clinical and regulatory roadmap. He will oversee advancement of AB-101, Alera’s novel therapy for MCT-8 deficiency, as the company works to bring new hope to patients and families affected by this devastating rare neurodevelopmental disorder. - June 04, 2026 - Alera Bio
SPARK Industries Announces New MRI Signal Analysis Platform for Neurological Disease and Cancer Research
SPARK Industries announced advancements in its patent-pending MRI signal-analysis platform designed to detect previously unresolved neurological and structural signatures within raw MRI data. Internal validation across 1,000+ clinical MRI cases involving TBI, Alzheimer’s, Parkinson’s, and prostate cancer demonstrated consistent signal relationships associated with known disease states. SPARK is now pursuing blinded third-party validation trials. - May 27, 2026 - SPARK Industries Corporation
HourScript Launches Clinical Services Platform for Pharmacies
Category creating solution gives community and advanced practice pharmacists the clinical workflow, EHR integration, and billing infrastructure needed to fully exercise their prescriptive authority — closing the gap between legal authority and real-world practice. - May 14, 2026 - HourScript
Mediprocity and SuiteRx Announce Secure Messaging Integration Into Pharmacy Management Software
Mediprocity is excited to announce a partnership with SuiteRx. Mediprocity’s secure messaging tool is now available through a seamless integration into SuiteRx pharmacy management software. The integration promises robust, instant, HIPAA-secure collaboration that streamlines workflows for... - May 14, 2026 - Mediprocity
Langham Logistics Opens Largest Pharmaceutical Cooler in the US
Central Indiana is now home to the largest pharma-grade 2°–8°C cooler environment in the United States. - May 04, 2026 - Langham Logistics
Parvus Therapeutics Initiates First-in-Human Clinical Trial of PVT401 for Inflammatory Bowel Disease
PVT401, a peptide-MHC nanomedicine, is the second Parvus drug candidate to enter clinical trials. - April 30, 2026 - Parvus Therapeutics U.S., Inc.
Last Chance for Global Pharma to Tap China’s Fast-Growing FDF Market at PHARMCHINA This May
PHARMCHINA 2026 (May 13–15, Shanghai) brings 2,000+ exhibitors together as a key gateway to China’s fast‑growing FDF market, offering global pharma firms critical sourcing, partnering, and regulatory insights before mid‑year decisions close. - April 28, 2026 - RX
Curvo Unveils New Brand Following Integration with BroadJump, Advancing Healthcare Supply Chain Tech
Unified company introduces evolved identity and expanded capabilities to help providers and suppliers make fair, fact-based decisions. - April 21, 2026 - Curvo
Radiopharmaceutical Manufacturers and Theranostics Alliance (RMTA) Advances Federal Policy in Radiopharmaceuticals and Theranostics
New Division of NEMA Focused on Strengthening Personalized Care for Patients - April 14, 2026 - Radiopharmaceutical Manufacturers and Theranostics Alliance (RMTA)
Alera Bio Announces Exclusive Licensing Agreement with BLA Technology to Expand Thyroid Hormone Intellectual Property Portfolio
Alera Bio has secured an exclusive global license from BLA Technology, LLC for thyroid hormone-related IP, strengthening its platform for MCT-8 deficiency. The deal expands Alera’s ability to target both neurological and systemic disease drivers, supports its lead program AB-101, reduces development risk, and enables future pipeline growth. - April 09, 2026 - Alera Bio
PRISM ALS: New Stem Cell Models Could Transform Research Into Treatments for MND/ALS
PRISM ALS is a new global initiative designed to accelerate the discovery of effective treatments for ALS/MND by improving access to specially grown, patient-derived stem cell models that better reflect the biological diversity of the disease. - March 31, 2026 - ALS Therapy Development Institute
Kamal Biswas Joins Regller as Chief Executive Officer to Redefine FDA-Regulated Manufacturing Quality with AI
Regller LLC, an AI-driven quality maturity SaaS platform for FDA-regulated industries, today announced the appointment of Kamal Biswas as its Chief Executive Officer. Kamal co-founded Regller and previously served on its board. With over 25 years of leadership experience across life sciences and technology, he brings deep expertise in pharmaceutical manufacturing, quality and compliance, management consulting to major pharma companies, and enterprise-scale AI and digital transformation. - March 31, 2026 - Regller
SignaBlok Receives Orphan Drug Designation from FDA for a First-in-Class TREM-1 Peptide Inhibitor for the Treatment of Retinopathy of Prematurity
SignaBlok, Inc., a preclinical stage biotechnology company pioneering novel, first-in-class peptide therapies for multiple inflammation-associated diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the Company’s TREM-1 peptide... - March 27, 2026 - SignaBlok, Inc.
Medical Industry Websites Compete for Digital Excellence in the WebAwards
The Web Marketing Association has opened entries for the 30th Annual WebAward Competition, inviting hospitals, medical practices, and healthcare organizations worldwide to compete for recognition as the best medical websites of 2026. Websites will be evaluated on design, innovation, usability, and technology. Winners gain industry recognition and valuable benchmarking insights. Entry deadline: May 29, 2026. - March 27, 2026 - Web Marketing Association
SignaBlok to Present Novel Approach to Preventing Cancer Recurrence at the 2026 American Association for Cancer Research (AACR) Annual Meeting
• In experimental pancreatic cancer, macrophage-targeted but not cell-unspecific TREM-1 inhibitor: 1) prevents cancer recurrence, improves complete response rate and survival, when administered in a time window of 7 days after standard-of-care (SOC) chemotherapy, and 2) reverses immunosuppression and overcomes cancer resistance to anti-PD-L1 immunotherapy - March 26, 2026 - SignaBlok, Inc.
Komal Medical Launches Direct Dawai for Online Pharmacy in Jaipur
Komal Medical & Provision Store is a familiar and trusted name in Jaipur. The store has a strong presence in the city, not for now, but for many years. It is known for its reliable service and genuine medicine, with an aim for maximum client satisfaction. Daily, hundreds of people buy... - February 28, 2026 - Direct Dawai
Thar Process Unveils New Line of CO2 Bulk Delivery Systems for Any Prep SFC and Pilot Scale SFE Users
Thar has a 35-year history of building automated supercritical systems and operating R&D labs. For many years, Thar also built CO2 delivery systems to make it easier for any client to access CO2 without the inconvenience of CO2 bottles/tanks inside the lab. This automation provides a fast return on investment for company's trying to mitigate labor costs and safety risks. - February 13, 2026 - Thar Process
Bio-Neuroscience 2026 Selects 12 Pioneering Companies to Present at Premier Global Neuroscience Drug Development Summit
Bio-Neuroscience today announced the selection of 12 neuroscience drug development companies to present at Bio-Neuroscience 2026, the premier global gathering of neuroscience innovation leaders, investors, and pharmaceutical executives. The companies were chosen from a competitive international field following rigorous evaluation of their scientific innovation, clinical progress, therapeutic approach, and commercial potential. - February 04, 2026 - Broadreach Global LLC
I Holland Celebrates 80 Years of Excellence with a Global Series of Free Seminars
In 2026, I Holland proudly reaches an exciting milestone: 80 years of excellence in tablet compression tooling. Founded in 1946, I Holland has spent eight decades advancing tablet compression technology, sharing industry-leading expertise, and supporting customers around the world. To celebrate... - January 29, 2026 - I Holland Ltd.
INTERPHEX WEEK TOKYO 2026 Expands Pharma Innovation with CMO/CDMO Expo
INTERPHEX WEEK TOKYO, Japan’s largest pharmaceutical and biotech show, will take place from May 20 to 22, 2026, at Makuhari Messe, bringing together a comprehensive range of products and services related to pharmaceuticals and regenerative medicine, and is expected to attract approximately... - January 14, 2026 - RX
CanVeer Biopharma Launches Validation Program for Flagship Neonatal Therapeutic and Appoints Executive Team
CanVeer announces the launch of the validation program for its flagship product, AlveoShield™ (Investigational New Drug). The program targets preterm newborns with or at risk of developing bronchopulmonary dysplasia (BPD). Bronchopulmonary dysplasia is a chronic respiratory disease affecting preterm neonates who require assisted ventilation. AlveoShield™ is designed to potentially prevent and treat BPD. CanVeer also announces the appointment of Sherif Louis as CEO and Behzad Yeganeh as CSO. - January 13, 2026 - CanVeer Biopharma Inc.
Pharmacy XD Launches Nationally Licensed Direct-to-Patient Mail Order Pharmacy and Distribution Platform - Headquartered in Florida’s Fastest-Growing Healthcare Corridor
Pharmacy XD LLC, a fully licensed Florida Department of Health–approved national mail order pharmacy and distribution facility, today officially announces its direct-to-patient (DTP) platform. Positioned in the heart of one of Florida’s most dynamic healthcare and life sciences... - January 08, 2026 - Pharmacy XD LLC
Cumberland Biotherapeutics Announces U.S. Launch of FDA Cleared DentoClude F, Complimentary Practice Program, and New Investor Fundraising Initiative
Cumberland Biotherapeutics, LLC, a dental innovation company integrating advanced bioactive glass with botanicals, today announced the U.S. launch of DentoClude F; DentoClude F is marketed under a commercial name for the Occlude® F Dentin Tubule Agent, which received FDA 510(k) clearance under... - December 30, 2025 - Cumberland Biotherapeutics, Inc
Biostem Pharma Private Limited Becomes a Preferred Partner for Third-Party Pharma Manufacturing in India
Biostem Pharma Private Limited strengthens its position as a preferred partner for third-party pharma manufacturing in India. The company offers WHO-GMP-compliant production of tablets, capsules, syrups, and topical formulations, catering to both startups and established pharma brands. - December 29, 2025 - Biostem Pharma Pvt Ltd
Curasia Medilabs Private Limited Offers Monopoly-Based PCD Pharma Franchise Opportunities
Curasia Medilabs Private Limited announces monopoly-based PCD pharma franchise opportunities, offering exclusive territories, a diversified product range, and structured partner support across India. - December 27, 2025 - Curasia Medilabs Pvt. Ltd.